Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and other comparators in patients with type 2 diabetes and obesity.
Tirzepatide is a dual-acting hormone medication (GIP/GLP-1) that offers even greater weight loss than semaglutide (up to 21% in trials). It is administered as a once-weekly injection, starting at a low dose and increasing every 4 weeks. It is particularly effective for patients with type 2 diabetes and obesity, improving both blood sugar and weight significantly more than other comparators.
Across the SURPASS phase 3 programme versus placebo and active comparators, including semaglutide, tirzepatide has shown superior dose-dependent reductions in HbA1c levels up to 2.5% and body weight up to 13%, compared with all comparators [88-91].
Why this rating
Supported by Phase III trials (SURPASS, SURMOUNT) comparing directly to other drugs.
Source
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son et al. · Endocrinology and Metabolism · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →